The rationale of this research stems from the growing interest in the design of non-toxic fluorescent probes that can exploit cancer-specific metabolic features, particularly the elevated expression of fructose transporters (e.g., GLUT5) in certain tumor types like breast cancer. Here, SLC2A5 is linked to breast carcinoma.